Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company's New Sham Tip for Pivotal PURSUIT Trial - BioSpace

Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company's New Sham Tip for Pivotal PURSUIT Trial  BioSpace

Comments

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management